KLF4 and hepatocellular carcinoma: However, when regorafenib is applied in treatment of HCC, it causes inhibition of p38 MAPK axis to downregulate expression level of its downstream targets including Creb1 and Klf4 to suppress M2 polarization in enhancing anti-tumor immunity in HCC [212].